Literature DB >> 21276105

Cost of diabetes and its complications in Thailand: a complete picture of economic burden.

Susmita Chatterjee1, Arthorn Riewpaiboon, Piyanuch Piyauthakit, Wachara Riewpaiboon, Kuanoon Boupaijit, Niphaphat Panpuwong, Vorachai Archavanuntagul.   

Abstract

Diabetes is a common metabolic disorder with increasing burden in Thailand. The chronic nature along with associated complications makes the disease very costly. In Thailand, there exist some studies on cost of diabetes; however, those studies estimated the cost either from provider or from patient perspective. In order to capture the complete picture of economic burden caused by diabetes, using prevalence-based approach; the present study estimated the cost of illness of diabetes from societal perspective, the broadest viewpoint covering all costs irrespective of who incur them. Data were collected from 475 randomly selected diabetic patients who received treatment from Waritchaphum hospital in Sakhon Nakhon province of Thailand during 2007-2008 with a response rate of 98%. A micro-costing approach was used to calculate the cost. The direct medical cost was calculated by multiplying the quantity of medical services consumed by their unit costs while indirect cost was calculated by using human capital approach. The total cost of illness of diabetes for 475 study participants was estimated as USD 418,696 for the financial year 2008 (1 USD = 32 THB). Of this, 23% was direct medical cost, 40% was direct non-medical cost and 37% was indirect cost. The average cost of illness per diabetic patient was USD 881.47 in 2008 which was 21% of per capita gross domestic product of Thailand. Existence of complications increased the cost substantially. Cost of informal care contributed 28% of total cost of illness of diabetes. Therefore, the disease not only affected the individual but also the family members, friends and neighbours. The economic and social burden of the disease therefore emphasises the need for initiatives to prevent the disease prevalence and counselling to the diabetic patients to prevent the progression of the disease and its devastating complications.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21276105     DOI: 10.1111/j.1365-2524.2010.00981.x

Source DB:  PubMed          Journal:  Health Soc Care Community        ISSN: 0966-0410


  27 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Economic burden of bacteremic melioidosis in eastern and northeastern, Thailand.

Authors:  Saithip Bhengsri; Jongkol Lertiendumrong; Henry C Baggett; Somsak Thamthitiwat; Wirongrong Chierakul; Kanjana Tisayaticom; Kittisak Tanwisaid; Somrak Chantra; Jaranit Kaewkungwal
Journal:  Am J Trop Med Hyg       Date:  2013-06-24       Impact factor: 2.345

Review 3.  Diabetes in Thailand: Status and Policy.

Authors:  Sirimon Reutrakul; Chaicharn Deerochanawong
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

4.  Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.

Authors:  Chaicharn Deerochanawong; Kriengsak Vareesangthip; Dilok Piyayotai; Dittaya Thongsuk; Nuch Pojchaijongdee; Unchalee Permsuwan
Journal:  Diabetes Ther       Date:  2021-06-09       Impact factor: 2.945

Review 5.  Diabetes management in Thailand: a literature review of the burden, costs, and outcomes.

Authors:  Chaicharn Deerochanawong; Alessandra Ferrario
Journal:  Global Health       Date:  2013-03-14       Impact factor: 4.185

6.  Predicting prediabetes in a rural community: a survey among the Karen ethnic community, Thasongyang, Thailand.

Authors:  Thaworn Lorga; Myo Nyein Aung; Prissana Naunboonruang; Payom Thinuan; Nara Praipaksin; Tida Deesakul; Utumporn Inwan; Tawatchai Yingtaweesak; Pratumpan Manokulanan; Srisomporn Suangkaew; Apiradee Payaprom
Journal:  Int J Gen Med       Date:  2012-03-01

7.  Costing of diabetes mellitus type II in Cambodia.

Authors:  Steffen Flessa; Anika Zembok
Journal:  Health Econ Rev       Date:  2014-11-01

Review 8.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Authors:  Till Seuring; Olga Archangelidi; Marc Suhrcke
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

Review 9.  Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review.

Authors:  Elizabeth D Brouwer; David Watkins; Zachary Olson; Jane Goett; Rachel Nugent; Carol Levin
Journal:  BMC Public Health       Date:  2015-11-26       Impact factor: 3.295

Review 10.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.